In November 2025, Abbott struck an agreement to acquire Exact Sciences for approximately $21 billion. Madison, Wisconsin–based Exact Sciences develops cancer screening and diagnostic tests. Its ...

Biotech heavyweight Gilead Sciences is set to acquire a Rockville-area cancer therapy developer in a deal valued at nearly $8 billion.

Roivant Sciences Ltd. (NASDAQ:ROIV) is one of the most promising low-cost stocks to buy now. On February 10, Citi raised its price target for Roivant Sciences to $35 from $26 while maintaining a Buy ...

Analysts' ratings for Roivant Sciences (NASDAQ:ROIV) over the last quarter vary from bullish to bearish, as provided by 4 analysts. Summarizing their recent assessments, the table below illustrates ...

SOUTH BEND — Notre Dame Federal Credit Union and Catholic United Financial Credit Union have announced their intent to merge, according to a press release. The proposed merger has been approved by ...

Rashes and lesions caused by cutaneous sarcoidosis can cover much of the body, sometimes becoming disfiguring. There are no FDA-approved treatments for this rare disease, which has been overlooked by ...

Roivant Sciences is upgraded to Buy after strong Phase 2 BEACON data for brepocitinib in cutaneous sarcoidosis, highlighting blockbuster potential. Brepocitinib's once-daily oral profile and robust ...

(RTTNews) - Shares of Roivant Sciences Ltd. (ROIV) are climbing about 17 percent on Friday morning trading over the announcement of positive results from the Phase 2 study of brepocitinib in cutaneous ...

Shares of Roivant Sciences were higher after the company released positive results from a phase-two study of its brepocitinib treatment for cutaneous sarcoidosis, a skin disease. The stock rose 14% to ...

Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...

As Priovant works toward approval of potential blockbuster brepocitinib as a treatment for dermatomyositis, the North Carolina biotech has presented promising results for the TYK2/JAK1 inhibitor in ...